Clay Gill named president of Beaufort
NORFOLK, VA., May 13, 2015—Beaufort, LLC, a contract research organization (CRO), has announced that Clay Gill has been promoted to president of the company.
“This appointment constitutes a great step for Beaufort, as we further position our organization as an industry-leading CRO,” said Beaufort Chairman and CEO Alfred F. Ritter, Jr.
Gill joined Beaufort in 2010 and is responsible for leading Beaufort’s global operations in clinical and regulatory services, quality solutions and staffing solutions. Through her leadership, passion and vision, she successfully manages multidisciplinary teams that deliver creative and effective solutions to complex and evolving business challenges.
“Her ability to deftly align sales, marketing and operations while keenly understanding a client’s individual needs is a critical factor in helping Beaufort consistently deliver program success for our clients,” commented Ritter.
About Beaufort, LLC
Beaufort, LLC, is a contract research organization that provides in vitro diagnostic, medical device and biopharmaceutical clinical and regulatory services, and a full range of quality solutions and staffing solutions. For more than a decade, companies worldwide have trusted Beaufort for its client-oriented approach to research. With operations spanning the globe, Beaufort has a proven track record working closely with clients and regulatory agencies internationally to bring complex and therapeutic-specific products to market. Learn more at BeaufortCRO.com.